Ignite Creation Date:
2024-05-06 @ 1:35 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01846624
Status:
TERMINATED
Last Update Posted:
2018-09-27
First Post:
2013-04-30
Brief Title:
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor:
David Iberri
Organization:
Stanford University
Study Overview
Official Title:
A Phase 2 Study of Decitabine in Combination With Midostaurin PKC412 for Elderly Patients With Newly Diagnosed FLT3-ITDTKD Positive Acute Myeloid Leukemia
Status:
TERMINATED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Accrual factor
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 2 study evaluates the sequential combination of decitabine then midostaurin for the treatment of newly-diagnosed acute myeloid leukemia AML in older patients
Detailed Description:
Treatment with decitabine a cytidine analog then midostaurin a multi-target protein kinase inhibitor PKI may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HEMAML0022 | REGISTRY | OnCore | None |